HPP vs IMMX Comparison

Hudson Pacific Properties Inc is a vertically integrated real estate investment trust offering end-to-end real estate solutions for dynamic tenants in the synergistic, converging and secular growth industries of tech and media. It acquires, repositions, develops and operates sustainable high-quality office studio properties in high-barrier-to-entry tech and media epicenters. Its primary investment markets include Los Angeles, the San Francisco Bay Area, Seattle, New York and Vancouver, British Columbia. Its segments include Office properties and related operations and Studio properties and related operations. The majority of the revenue is derived from Office properties and related operations segment.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.